Acipimox

Acipimox

Clinical data
Trade names	Olbetam
AHFS/Drugs.com	UK Drug Information
Routes of administration	Oral
ATC code	C10AD06 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	100%
Protein binding	None
Metabolism	None
Elimination half-life	Phase 1: 2 hrs Phase 2: 12–14 hrs
Excretion	Renal
Identifiers
IUPAC name 5-Carboxy-2-methyl-1-oxidopyrazin-1-ium
CAS Number	51037-30-0 Y
PubChem CID	5310993
IUPHAR/BPS	1596
ChemSpider	4470534 Y
UNII	K9AY9IR2SD
KEGG	D07190 Y
ChEMBL	ChEMBL345714 Y
CompTox Dashboard (EPA)	DTXSID2046202
ECHA InfoCard	100.051.736
Chemical and physical data
Formula	C6H6N2O3
Molar mass	154.125 g·mol−1
3D model (JSmol)	Interactive image
SMILES [O-][n+]1c(cnc(C(=O)O)c1)C
InChI InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10) Y Key:DJQOOSBJCLSSEY-UHFFFAOYSA-N Y
(verify)

Acipimox (trade name Olbetam in Europe) is a niacin derivative used as a lipid-lowering agent. It reduces triglyceride levels and increases HDL cholesterol. It may have less marked adverse effects than niacin, although it is unclear whether the recommended dose is as effective as standard doses of niacin.